SCHEMBL420585

SCHEMBL420585

COc1cc(/C=C2/C(=O)N(c3cccc(C(=O)O)c3)N=C2C)ccc1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.72
MEN1 O00255 10/20 0.72
L3MBTL1 Q9Y468 4/20 0.64
POLB P06746 2/20 0.64
PSMD14 O00487 1/20 0.61
KAT8 Q9H7Z6 2/20 0.59
MAPT P10636 5/20 0.58
ALDH1A1 P00352 4/20 0.58
GAA P10253 4/20 0.58
KDM4E B2RXH2 1/20 0.58
THRB P10828 1/20 0.58
HTT P42858 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
MAPK1 P28482 1/20 0.57
MDM2 Q00987 1/20 0.57
GPR55 Q9Y2T6 1/20 0.57
PKM P14618 2/20 0.55
HPGD P15428 1/20 0.55
XPA P23025 1/20 0.55
AMY1A P0DUB6 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22523764 0.92 KMT2A (0.80) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL446664 0.90 KMT2A (0.66) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL446663 0.90 KMT2A (0.66) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL420579 0.90 KMT2A (0.66) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL11045187 0.89 KMT2A (0.81) KMT2AMEN1L3MBTL1POLBKAT8
SCHEMBL24212685 0.87 KMT2A (0.81) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL12768578 0.82 KMT2A (0.71) KMT2AMEN1L3MBTL1POLBKAT8
SCHEMBL245319 0.81 KMT2A (0.66) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL245318 0.81 KMT2A (0.66) KMT2AMEN1L3MBTL1POLBPSMD14
SCHEMBL12417244 0.79 KAT8 (0.66) KMT2AMEN1L3MBTL1POLBKAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123577-A1 Inhibitor of protein modification products formation SERPINB6, PROC, PLPBP KMT2A 2334/4885MEN1 1277/4885L3MBTL1 1078/4885
US-20110028470-A1 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KMT2A 1703/4885MEN1 4818/4885L3MBTL1 3146/4885
US-20120065198-A2 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KMT2A 1703/4885MEN1 4818/4885L3MBTL1 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.